PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 157 filers reported holding PROTAGONIST THERAPEUTICS INC in Q4 2023. The put-call ratio across all filers is 0.17 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,954 | +629.4% | 177,125 | +1108.7% | 0.03% | +833.3% |
| Q2 2023 | $405 | -58.8% | 14,654 | -83.7% | 0.00% | -78.6% |
| Q4 2022 | $983 | -99.9% | 90,107 | -17.2% | 0.01% | +16.7% |
| Q3 2022 | $918,000 | +4.4% | 108,876 | -2.0% | 0.01% | +9.1% |
| Q2 2022 | $879,000 | +177.3% | 111,126 | +607.8% | 0.01% | +266.7% |
| Q4 2020 | $317,000 | -16.4% | 15,701 | -47.9% | 0.00% | -89.3% |
| Q1 2019 | $379,000 | +294.8% | 30,119 | +112.1% | 0.03% | +300.0% |
| Q4 2018 | $96,000 | – | 14,200 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $84,864,191 | 21.18% |
| Cannon Global Investment Management, LLC | 69,900 | $2,422,035 | 11.28% |
| ADAR1 Capital Management, LLC | 1,603,932 | $55,576,244 | 10.49% |
| Checkpoint Capital L.P. | 355,000 | $12,300,750 | 7.42% |
| Fairmount Funds Management LLC | 931,890 | $32,289,989 | 3.65% |
| BVF INC/IL | 3,319,290 | $115,013,399 | 3.22% |
| RTW INVESTMENTS, LP | 5,286,404 | $183,173,899 | 2.84% |
| Kynam Capital Management, LP | 800,000 | $27,720,000 | 2.14% |
| 683 Capital Management, LLC | 604,449 | $20,944,158 | 1.58% |
| Birchview Capital, LP | 48,000 | $1,663,200 | 1.54% |